Open Access
Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
Marc Humbert,Richard Beasley,J. Ayres +2 more
- pp 425-434
About:
The article was published on 2017-01-01 and is currently open access. It has received 848 citations till now. The article focuses on the topics: Omalizumab.read more
Citations
More filters
Journal ArticleDOI
Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
Hector Ortega,Steven W. Yancey,Bhabita Mayer,Necdet B Gunsoy,Oliver N. Keene,Eugene R. Bleecker,Christopher E. Brightling,Ian D. Pavord +7 more
TL;DR: An analysis of data from two randomised, double-blind, placebo-controlled studies of at least 32 weeks duration has shown a close relationship between baseline blood eosinophil count and clinical efficacy of mepolizumab in patients with severe eOSinophilic asthma and a history of exacerbations.
Journal ArticleDOI
The mechanisms, diagnosis, and management of severe asthma in adults
TL;DR: The importance of identifying underlying causative factors and the recent introduction of novel therapeutic approaches, including the targeting of immunoglobulin E and tumour necrosis factor alpha with biological agents, emphasise the need for careful phenotyping of patients with severe disease to target improved management of the individual patient's needs.
Journal Article
Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy
Nicola A. Hanania,Oral Alpan,Daniel L. Hamilos,John J. Condemi,Irmarie Reyes-Rivera,Jin Zhu,Karin Rosén,Mark D. Eisner,Dennis A. Wong,William W. Busse +9 more
TL;DR: In this paper, a randomized trial evaluated the efficacy of inhaled corticosteroids (ICS) and long-acting β2-agonists (LABAs) for severe asthma in some patients.
Journal ArticleDOI
GINA guidelines on asthma and beyond.
Jean Bousquet,T. J. H. Clark,Suzanne S. Hurd,Nikolai Khaltaev,C. Lenfant,Paul M. O'Byrne,A. Sheffer +6 more
TL;DR: Although asthma guidelines may not be perfect, they appear to be the best vehicle available to assist primary care physicians and patients to receive the best possible care of asthma.
Journal ArticleDOI
Asthma phenotypes and the use of biologic medications in asthma and allergic disease: The next steps toward personalized care
Merritt L. Fajt,Sally E. Wenzel +1 more
TL;DR: It is concluded that further refinement of type 2 therapies to specific type 2 phenotypes and novel approaches for patients without type 2 inflammation are needed for asthma and allergic disease treatment.
References
More filters
Journal ArticleDOI
Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials.
Elizabeth F. Juniper,Gordon H. Guyatt,Robert S. Epstein,Penelope J. Ferrie,Roman Jaeschke,T K Hiller +5 more
TL;DR: A questionnaire suitable for all adults with asthma and designed to be responsive to within subject change and therefore may be used as a measure of outcome in clinical trials in asthma is developed.
Allergy, rhinitis, other respiratory diseases Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
William W. Busse,Jonathan Corren,Bobby Q. Lanier,Margaret McAlary,Angel FowlerTaylor,Giovanni Della Cioppa,Niroo Gupta,Fort Worth +7 more
TL;DR: Omalizumab as discussed by the authors is a recombinant humanized anti-IgE mAb, which forms complexes with free IgE, blocking its interaction with mast cells and basophils.
Journal ArticleDOI
Proceedings of the ATS Workshop on Refractory Asthma Current Understanding, Recommendations, and Unanswered Questions
Sally E. Wenzel,John V. Fahy,Charles G. Irvin,Stephen P. Peters,Sheldon L. Spector,Stanley J. Szefler,Thomas B. Casale,Michelle M. Cloutier,Jack A. Elias,Mark C. Liu,Virginia Taggert +10 more
TL;DR: The proceedings of an American Thoracic Society (ATS)-sponsored workshop are hoped to serve as an aid to begin to define, understand, and manage these refractory patients.
Journal ArticleDOI
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics
Markus Solèr,J. Matz,Robert G. Townley,R. Buhl,J. O'Brien,Howard Fox,J. Thirlwell,N. Gupta,G. Della Cioppa +8 more
TL;DR: Results indicate that omalizumab therapy safely improves asthma control in allergic asthmatics who remain symptomatic despite regular use of inhaled corticosteroids and simultaneous reduction in Corticosteroid requirement.